Alisha Holtzhausen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8906582/publications.pdf

Version: 2024-02-01

687363 940533 1,161 21 13 16 citations h-index g-index papers 21 21 21 2072 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Paracrine Wnt5a- \hat{l}^2 -Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization. Immunity, 2018, 48, 147-160.e7. | 14.3 | 185 |
| 2 | Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. Cancer Immunology Research, 2015, 3, 1082-1095. | 3.4 | 147 |
| 3 | A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy. Journal of Clinical Investigation, 2020, 130, 2570-2586. | 8.2 | 134 |
| 4 | Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. Journal of Clinical Investigation, 2018 , 128 , 2356 - 2369 . | 8.2 | 118 |
| 5 | Type III TGF- \hat{l}^2 receptor downregulation generates an immunotolerant tumor microenvironment. Journal of Clinical Investigation, 2013, 123, 3925-3940. | 8.2 | 94 |
| 6 | TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti–PD-1 Therapy in Melanoma. Cancer Immunology Research, 2019, 7, 1672-1686. | 3.4 | 85 |
| 7 | Stromal Fibroblasts Mediate Anti–PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma. Cancer Immunology Research, 2018, 6, 1459-1471. | 3.4 | 81 |
| 8 | Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB Journal, 2014, 28, 1248-1267. | 0.5 | 80 |
| 9 | Factor XIIIAâ€"expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking. Nature Communications, 2018, 9, 1988. | 12.8 | 69 |
| 10 | Type III TGF- \hat{l}^2 Receptor Enhances Colon Cancer Cell Migration and Anchorage-Independent Growth. Neoplasia, 2011, 13, 758-IN28. | 5.3 | 56 |
| 11 | Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. Cell Reports, 2021, 35, 109071. | 6.4 | 35 |
| 12 | MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression. Nature Communications, 2019, 10, 1515. | 12.8 | 25 |
| 13 | Combinatorial TGF-Î ² signaling blockade and anti-CTLA-4 antibody immunotherapy in a murine BRAF ^{V600E} -PTEN-/- transgenic model of melanoma Journal of Clinical Oncology, 2014, 32, 3011-3011. | 1.6 | 25 |
| 14 | Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy. Frontiers in Immunology, 2014, 5, 438. | 4.8 | 12 |
| 15 | Overcoming Immunotherapy Resistance by Targeting the Tumor-Intrinsic NLRP3-HSP70 Signaling Axis. Cancers, 2021, 13, 4753. | 3.7 | 9 |
| 16 | Role of the Wnt- \hat{l}^2 -catenin signaling pathway in melanoma-mediated dendritic cell tolerization. , 2013, 1, P153. | | 3 |
| 17 | Targeting the Wnt5a- \hat{l}^2 -catenin pathway in the melanoma microenvironment to augment checkpoint inhibitor immunotherapy Journal of Clinical Oncology, 2015, 33, 3054-3054. | 1.6 | 2 |
| 18 | Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events. Journal of Immunotherapy, 0, Publish Ahead of Print, . | 2.4 | 1 |

| # | Article | IF | CITATIONS |
|----|---|----|-----------|
| 19 | Abstract 3972: The role of the TGF- \hat{I}^2 type III receptor in colon carcinogenesis. , 2010, , . | | O |
| 20 | Abstract 3548: Loss of the type III TGF- \hat{l}^2 receptor during cancer progression generates an immunotolerant tumor microenvironment: Translational implications for TGF- \hat{l}^2 inhibition and immunotherapy biomarker development. , 2012, , . | | 0 |
| 21 | Abstract 3035: Bone morphogenetic proteins signal through Smad2 and Smad3 to regulate cell migration and proliferation. , 2012, , . | | O |